Matches in SemOpenAlex for { <https://semopenalex.org/work/W186908391> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W186908391 endingPage "86" @default.
- W186908391 startingPage "179" @default.
- W186908391 abstract "The bcr-abl oncogene is the molecular counterpart of the Philadelphia chromosome (Ph), which is detected in > 95% of patients with chronic myelogenous leukemia (CML) and 20-30% of adults with acute lymphoblastic leukemia (ALL). Leukemic cells from patients with CML express the p210 form of the bcr-abl oncogene, whereas in adult Ph+ ALL approximately 50% of cases express the p190 form of the bcr-abl oncogene, and the other 50% express the same p210 gene as is found in CML. In this study, we have designed hairpin ribozymes (RZs) specific for the p190 form of the bcr-abl oncogene to inhibit the growth of a p190 Ph+ ALL cell line, Sup-B15. The RZs cleave p190 RNA substrate in a cell-free in vitro assay. In the presence of the liposome, DMRIE-C, the RZs are protected from serum mediated catalysis in vitro. Anti-p190 RZs transfected with DMRIE-C as the vector into K562 cells, which express the p210 bcr-abl oncogene, are stable intracellularly for up to 96 hours. Up to 33% of the DMRIE-C and RZ mixtures are taken up by Sup-B15 cells cultured in suspension. Expression of the p190 bcr-abl protein product is specifically inhibited as demonstrated by Western blot analysis. Cell growth of the Sup-B15 cells is completely inhibited by anti-p190 RZs over four days in culture. Anti-p210 RZs have no significant effect on bcr-abl protein expression or cell growth by Sup-B15 cells. RZs may have a role in purging stem cell populations collected from patients with Ph+ ALL in the context of autologous bone marrow transplantation." @default.
- W186908391 created "2016-06-24" @default.
- W186908391 creator A5015550752 @default.
- W186908391 creator A5023141575 @default.
- W186908391 creator A5032761450 @default.
- W186908391 creator A5035787488 @default.
- W186908391 creator A5084690441 @default.
- W186908391 creator A5090849737 @default.
- W186908391 date "1997-10-01" @default.
- W186908391 modified "2023-09-23" @default.
- W186908391 title "Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene." @default.
- W186908391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9360779" @default.
- W186908391 hasPublicationYear "1997" @default.
- W186908391 type Work @default.
- W186908391 sameAs 186908391 @default.
- W186908391 citedByCount "11" @default.
- W186908391 countsByYear W1869083912023 @default.
- W186908391 crossrefType "journal-article" @default.
- W186908391 hasAuthorship W186908391A5015550752 @default.
- W186908391 hasAuthorship W186908391A5023141575 @default.
- W186908391 hasAuthorship W186908391A5032761450 @default.
- W186908391 hasAuthorship W186908391A5035787488 @default.
- W186908391 hasAuthorship W186908391A5084690441 @default.
- W186908391 hasAuthorship W186908391A5090849737 @default.
- W186908391 hasConcept C104317684 @default.
- W186908391 hasConcept C125418893 @default.
- W186908391 hasConcept C138626823 @default.
- W186908391 hasConcept C1491633281 @default.
- W186908391 hasConcept C153911025 @default.
- W186908391 hasConcept C171122931 @default.
- W186908391 hasConcept C203014093 @default.
- W186908391 hasConcept C2778461978 @default.
- W186908391 hasConcept C2778904597 @default.
- W186908391 hasConcept C2781018059 @default.
- W186908391 hasConcept C29537977 @default.
- W186908391 hasConcept C42362537 @default.
- W186908391 hasConcept C43907098 @default.
- W186908391 hasConcept C502942594 @default.
- W186908391 hasConcept C54355233 @default.
- W186908391 hasConcept C62478195 @default.
- W186908391 hasConcept C81885089 @default.
- W186908391 hasConcept C86803240 @default.
- W186908391 hasConcept C95444343 @default.
- W186908391 hasConceptScore W186908391C104317684 @default.
- W186908391 hasConceptScore W186908391C125418893 @default.
- W186908391 hasConceptScore W186908391C138626823 @default.
- W186908391 hasConceptScore W186908391C1491633281 @default.
- W186908391 hasConceptScore W186908391C153911025 @default.
- W186908391 hasConceptScore W186908391C171122931 @default.
- W186908391 hasConceptScore W186908391C203014093 @default.
- W186908391 hasConceptScore W186908391C2778461978 @default.
- W186908391 hasConceptScore W186908391C2778904597 @default.
- W186908391 hasConceptScore W186908391C2781018059 @default.
- W186908391 hasConceptScore W186908391C29537977 @default.
- W186908391 hasConceptScore W186908391C42362537 @default.
- W186908391 hasConceptScore W186908391C43907098 @default.
- W186908391 hasConceptScore W186908391C502942594 @default.
- W186908391 hasConceptScore W186908391C54355233 @default.
- W186908391 hasConceptScore W186908391C62478195 @default.
- W186908391 hasConceptScore W186908391C81885089 @default.
- W186908391 hasConceptScore W186908391C86803240 @default.
- W186908391 hasConceptScore W186908391C95444343 @default.
- W186908391 hasIssue "4" @default.
- W186908391 hasLocation W1869083911 @default.
- W186908391 hasOpenAccess W186908391 @default.
- W186908391 hasPrimaryLocation W1869083911 @default.
- W186908391 hasRelatedWork W1494081104 @default.
- W186908391 hasRelatedWork W2021296556 @default.
- W186908391 hasRelatedWork W2022192516 @default.
- W186908391 hasRelatedWork W2043122200 @default.
- W186908391 hasRelatedWork W2093484163 @default.
- W186908391 hasRelatedWork W2158410352 @default.
- W186908391 hasRelatedWork W2399190738 @default.
- W186908391 hasRelatedWork W2413667918 @default.
- W186908391 hasRelatedWork W4235881139 @default.
- W186908391 hasRelatedWork W4285094426 @default.
- W186908391 hasVolume "3" @default.
- W186908391 isParatext "false" @default.
- W186908391 isRetracted "false" @default.
- W186908391 magId "186908391" @default.
- W186908391 workType "article" @default.